A Study of M802 (HER2 and CD3) in HER2-Positive Advanced Solid Tumors

HER2-Positive Solid Tumors Clinical Trial

Official title:
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity Profiles of the Recombinant Anti-HER2 and Anti-CD3 Humanized Bispecific Antibody (M802) in HER2-Positive Advanced Solid Tumors

Status Not yet recruiting

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of different doses of M802 in patients with HER2-positive advanced solid tumors, and to determine the dose limiting toxicity (DLT) and the maximum tolerated dose (MTD) so as to provide basis for the recommended phase 2 dose (RP2D).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04501770
Study type	Interventional
Source	Wuhan YZY Biopharma Co., Ltd.
Contact	Xiong Wang
Phone	86-027-82668440
Email	wangxiong@yzybio.com
Status	Not yet recruiting
Phase	Phase 1
Start date	August 28, 2021
Completion date	December 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04189211` - A Clinical Trial of BAT8001 on Safety, Tolerability and Pharmacokinetics for Patients	Phase 1
Recruiting	`NCT04280341` - JS001 in Combination With RC48-ADC in Treatment of HER2-Positive Advanced Malignant Solid Tumors	Phase 1
Active, not recruiting	`NCT04278144` - A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT04660929` - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors	Phase 1
Completed	`NCT04521179` - Study of KN026 Combined With KN046 in Patients With Locally Advanced HER2-positive Solid Tumors	Phase 2